PGC Stock Overview
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health, aged care, and veterinary markets in Australia, New Zealand, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Paragon Care Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.32 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.15 |
| Beta | 1.44 |
| 1 Month Change | 21.70% |
| 3 Month Change | 57.32% |
| 1 Year Change | 24.04% |
| 3 Year Change | 50.00% |
| 5 Year Change | -26.70% |
| Change since IPO | 29.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PGC | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -2.3% | -3.7% | -2.2% |
| 1Y | 24.0% | -23.6% | 4.5% |
Return vs Industry: PGC exceeded the Australian Healthcare industry which returned -23.6% over the past year.
Return vs Market: PGC exceeded the Australian Market which returned 4.5% over the past year.
Price Volatility
| PGC volatility | |
|---|---|
| PGC Average Weekly Movement | 13.7% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PGC's share price has been volatile over the past 3 months.
Volatility Over Time: PGC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Walstab | www.paragoncare.com.au |
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health, aged care, and veterinary markets in Australia, New Zealand, and Asia. It operates through four segments: Diagnostic and Scientific, Devices, Capital and Consumables, and Service and Technology. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits.
Paragon Care Limited Fundamentals Summary
| PGC fundamental statistics | |
|---|---|
| Market cap | AU$217.06m |
| Earnings (TTM) | AU$10.31m |
| Revenue (TTM) | AU$317.03m |
21.1x
P/E Ratio0.7x
P/S RatioIs PGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGC income statement (TTM) | |
|---|---|
| Revenue | AU$317.03m |
| Cost of Revenue | AU$187.50m |
| Gross Profit | AU$129.52m |
| Other Expenses | AU$119.21m |
| Earnings | AU$10.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.015 |
| Gross Margin | 40.86% |
| Net Profit Margin | 3.25% |
| Debt/Equity Ratio | 44.5% |
How did PGC perform over the long term?
See historical performance and comparison